NeuroScientific
BIOPHARMACEUTICALS
ASX:NSB

ASX ANNOUNCEMENT
24 NOVEMBER 2022

Chairman's 2022 Annual General Meeting Address

Good afternoon ladies and gentlemen. Welcome to the 2022 AGM for NeuroScientific Biopharmaceuticals Limited. My name is Paul Rennie, the Chairman & Interim CEO of NeuroScientific. I will also Chair today's meeting. Thank you for taking the time to attend this afternoon.

It is now 1.00pm and there being a quorum present, I declare the meeting open for business. I confirm that the meeting has been properly constituted.

In opening the 2022 AGM I would like to introduce you to your Board of Directors: Mr Stephen Quantrill and Dr Anton Uvarov. The member of the Board standing for re-election today is Dr Anton Uvarov. I would also like to introduce the CFO & Company Secretary Ms Abby Macnish.

As this meeting is being conducted as a virtual meeting, I would like to welcome those shareholders that are joining us via zoom and ask that you please submit any questions or comments via the Q&A function which can be found at the bottom of your zoom screen.

Please start your question by typing your shareholding SRN or HIN. This will allow the moderator to identify you as a shareholder. If you would like to ask your question verbally, type your SRN or HIN and then type "I'd like to speak".

Once you have finished typing, please hit enter on your keyboard to send. When you submit a question or comment please start by typing which resolution it relates to so that it can be addressed at the appropriate time.

Questions which relate to the general business of the Company will be collected and addressed after the close of the formal business of the meeting.

I will now present a short update presentation and an opportunity for general questions and answers, before moving to the formal aspects of the meeting.

Interim CEO's 2022 Annual General meeting presentation

-ENDS-

For more information please contact:

Paul Rennie
Interim CEO & Chairman
NeuroScientific Biopharmaceuticals
ir@neuroscientific.com
+ 61 8 6382 1805

Lucas Robinson
Investor Relations
Corporate Storytime
lucas@corporatestorytime.com
+ 61 408 228 889

About NeuroScientific Biopharmaceuticals Ltd

NeuroScientific Biopharmaceuticals Limited (ASX: NSB) is a company developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The company's product portfolio includes EmtinB™, a therapeutic peptide initially targeting Alzheimer's disease and glaucoma, as well as other Emtin peptides (EmtinAc, EmtinAn, and EmtinBn) which have demonstrated similar therapeutic potential as EmtinB™. For more information, please visit www.neuroscientific.com

About EmtinB™

EmtinB™ is a peptide-based compound that binds to surface-based cell receptors from the LDLR family, activating intracellular signalling pathways that stimulate neuroprotection, neuroregeneration and modulate neuroinflammation. EmtinB™ is modelled on a specific active domain of the complex human protein called Metallothionein-IIA, which is produced as part of the human body's innate immune response to cell injury.

Our preclinical research has established that EmtinB™ is highly specific and selective for its target receptor, safe and well tolerated at high concentrations, and is able to penetrate the blood brain barrier. A series of Phase I clinical studies will be conducted to establish the safety profile of EmtinB™ in humans.

NeuroScientific
BIOPHARMACEUTICALS

NOVEL DRUG THERAPIES FOR
NEURODEGENERATIVE CONDITIONS

AGM PRESENTATION

NOVEMBER 2022 · ASX: NSB

neuroscientific.com

DISCLAIMER

The purpose of the presentation is to provide an update of the business of NeuroScientific Biopharmaceuticals Ltd ("NeuroScientific", or "the Company"). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Further information is available upon request.

The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information. Any forward-looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside NeuroScientific's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and NeuroScientific's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward-looking statements contained in this presentation with caution.

This presentation should not be relied on as a recommendation or forecast by NeuroScientific. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

Q&A FUNCTIONALITY

1. Click on the Q&A icon



2. Type your question in the new Q&A window



3. Hit enter on your keyboard to submit your message



To contact Automic support:
1300 816 159

AUTOMIC GROUP

NEUROSCIENTIFIC BIOPHARMACEUTICALS LTD

CAPITAL STRUCTURE

NSB	143.5m	16.8m
ASX Code	Shares on issue	Unlisted options
$14m	**$0.096**	**$4.2m**
Market capitalisation	Share price (20/11/22)	Net cash position (30/9/2022)

MAJOR SHAREHOLDERS



DEVELOPING NOVEL THERAPEUTICS FOR NEURODEGENERATIVE CONDITIONS

EMTINB™: LEAD DRUG CANDIDATE

- Peptide-based therapeutic with novel MOA for treating neurodegenerative conditions
- Potential first-in-class and disease modifying therapeutic for Multiple sclerosis

ADVANCED PIPELINE OF TREATMENT INDICATIONS

- Active clinical development program
- Preclinical proof of efficacy in Multiple sclerosis, Alzheimer's disease, and glaucoma

FINANCIAL & CORPORATE

- Strong cash position
- Experienced board and management team
- Major shareholders include McRae Investments and Alpha Swiss

LEADERSHIP & MANAGEMENT

BOARD & MANAGEMENT

Paul Rennie
Executive Chairman & Interim CEO
- Founder of Paradigm (ASX: PAR)
- Former COO of Mesoblast (ASX: MSB)

Stephen Quantrill
Non-Executive Director
- 20+ years corporate advisory
- Managing Director of McRae Investments

Dr Anton Uvarov
Non-Executive Director
- Founding Director of Actinogen (ASX: ACW)
- Former equities analyst with Citigroup, US

SENIOR MANAGEMENT

Dougal Thring
Chief Operating Officer
B.MedPharBio
M.PharmMed

Simon Scott
Director of Clinical Development
B.Sci M.PharmMed

Abby Macnish
Chief Financial Officer / Company Secretary
B.Com CFA

HREC SUBMISSION REFUSED ON THREE MATTERS

NSB understands the HREC decision, and we understand their position. The HREC explained the three reasons for the refusal were safety, purity of EmtinB™ and efficacy.

- **Safety**– local injection site tolerability was not satisfactorily demonstrated, with systemic safety not noted as a concern.

- **Purity of EmtinB™** – lack of clear identification of impurities and overall purity of the product was questioned. Peptide manufacturing is complex and holds no clear guidance on overall purity requirements.

- **Efficacy** – Key efficacy animal model was not accepted due to a different form of the EmtinB being used in this study from planned clinical product.

NSB NEXT STEPS FOR EMTINB™ (3-6 months)

- **Safety:** Two independent toxicologists (one US board certified and one with both US and EU board certification) to perform a thorough GAP analysis. Following completion of all required toxicology, a formal independent toxicology report opinion will be provided for revised HREC submission.

- **Purity of EmtinB™:** Full characterization of impurities is now complete. The Company is also conducting a full CMC regulatory GAP analysis. Next steps are for an EU/UK regulatory scientific meeting to support the purity of EmtinB.

- **Efficacy.** NSB will present efficacy data on the preclinical multiple sclerosis model. The data and the final report are due from the external provider by 28 February 2023.

NSB NEXT STEPS (3–6 months)

- **Interim CEO:** Paul Rennie appointed interim CEO to oversee the next 3–6 months whilst the company works to identify a permanent CEO.
- **Independent review:** The Company has engaged an independent team to conduct a full review of what occurred in the lead up to the failed HREC Submission.
- **Additional IP:** The Company plans to file at least 2 new patents for EmtinB™
- **Re-submission plans:** All concerns raised through the initial submission will be addressed and confirmed appropriate via independent expert review.
  A re-submission to an Australian HREC or an alternate geography, such as the MHRA (UK), will occur to undertake the planned Phase I trial.
- **In-licensing opportunity:** The Company plans to potentially in-license a new novel technology to expand the Company's pipeline.

PIVOTAL MILESTONES

KEY MILESTONES COMPLETED

- ✓ SAFETY & TOXICITY STUDIES IN ANIMALS (NEUROLOGY INDICATIONS)
- ✓ PRECLINICAL BIOMARKER PROGRAM – IDENTIFIED POTENTIAL PD & EFFICACY BIOMARKERS
- ✓ MANUFACTURING OF CLINICAL-GRADE (GMP) EMTINB™
- ✓ HREC APPROVAL TO COMMENCE EARLY-PHASE CLINICAL TRIAL
- ✓ FIRST SUBJECT RECRUITED FOR EARLY-PHASE CLINICAL TRIAL
- ✓ IND-ENABLING PROGRAM WITH COMPLETED GAP ANALYSIS

PIVOTAL MILESTONES

NEAR-TERM KEY MILESTONES

- PIVOTAL EFFICACY RESULTS FROM PRECLINICAL MULTIPLE SCLEROSIS MODEL
- COMPLETION OF EARLY-PHASE CLINICAL TRIAL
- HREC NEW SUBMISSION TO COMMENCE PHASE I CLINICAL TRIAL
- RECRUITMENT OF FIRST COHORT FOR PHASE I CLINICAL TRIAL
- FIRST HEALTHY VOLUNTEER DOSED IN PHASE I CLINICAL TRIAL
- ADDITIONAL PATENTS TO FURTHER COMMERCIAL VALUE OF IP PORTFOLIO
- ENGAGEMENT WITH POTENTIAL COMMERCIAL PARTNERS ON A POSSIBLE DEAL

NeuroScientific
BIOPHARMACEUTICALS

neuroscientific.com

For more information contact:

Abby Macnish – CFO and Company Secretary

E: Abby Macnish ir@neuroscientific.com

Paul Rennie- Chairman & Interim CEO

E: prennie@neuroscientific.com